Mylan Given Consensus Rating of “Buy” by Analysts (NYSE:MYL)
Shares of Mylan (NYSE:MYL) have received a consensus rating of “Buy” from the thirteen analysts that are currently covering the company, American Banking News.com reports. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $54.45.
Mylan (NYSE:MYL) traded up 0.56% on Friday, hitting $48.40. The stock had a trading volume of 331,623 shares. Mylan has a one year low of $34.82 and a one year high of $57.52. The stock’s 50-day moving average is $49.08 and its 200-day moving average is $49.79. The company has a market cap of $18.104 billion and a P/E ratio of 32.76.
Mylan (NYSE:MYL) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.69 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by $0.04. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.88 billion. During the same quarter in the previous year, the company posted $0.68 earnings per share. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. On average, analysts predict that Mylan will post $3.29 earnings per share for the current fiscal year.
MYL has been the subject of a number of recent research reports. Analysts at Leerink Swann cut their price target on shares of Mylan from $60.00 to $55.00 in a research note on Friday, August 8th. Separately, analysts at Keefe, Bruyette & Woods reiterated an “outperform” rating on shares of Mylan in a research note on Friday, August 8th. They now have a $55.00 price target on the stock, down previously from $60.00. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Mylan in a research note on Friday, August 8th. They now have a $49.00 price target on the stock.
Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.